Briviact is the latest drug to be approved in the European Union for the treatment of epilepsy and like the similar drug Keppra, it has been developed and manufactured by Belgian pharmaceutical company UCB Pharma. Like Keppra, Briviact is a drug which is part of the racetam family of medicines. A chemical analog of Keppra, Briviact is classed as an anti-convulsant which is the name given for those with anti-epileptic properties. Briviact, like Keppra, is currently licensed for the treatment of partial-onset epileptic seizures.
Off-Label Use - Racetam drugs are very popular among those interested in life extension, or else enhancing their cognitive processes such as memory, learning, concentration and productivity. With Briviact being very new to the scene, there is a relative paucity of data on its suitability for such purposes.
Briviact is absorbed both rapidly and near completely with a half life of 7-8 hours. With it recently being accepted as a monotherapy drug option in the USA, it is likely to grow to become a drug of choice for treating epileptic seizures. By reducing seizures, Briviact can help enhance life satisfaction and help stop epilepsy from robbing you of your time.
Briviact is prescribed for adults only, defined as people aged 16 years old and over suffering from epilepsy. Both men and women can take Briviact.
Briviact is usually dosed when starting, at a dose of 50mg twice daily. However, dosages will sometimes be adjusted by the physician supervising the patient's treatment with it being titrated up or down depending on factors such as patient history, age, hepatic status and bodyweight to list just a few.